Cite
HARVARD Citation
Gibiansky, E. et al. (2019). Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study. British journal of clinical pharmacology. 85 (9), pp. 1935-1945. [Online].